×
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
S&P 500   4,131.37 (+1.81%)
DOW   32,996.99 (+1.10%)
QQQ   306.80 (+2.50%)
AAPL   148.38 (+3.20%)
MSFT   270.67 (+1.79%)
FB   193.69 (+1.07%)
GOOGL   2,227.27 (+3.31%)
AMZN   2,265.00 (+1.96%)
TSLA   750.88 (+6.10%)
NVDA   186.37 (+4.40%)
BABA   93.08 (-1.48%)
NIO   16.39 (+2.25%)
AMD   101.11 (+2.39%)
CGC   4.89 (-11.89%)
MU   72.95 (+3.33%)
T   21.21 (-0.52%)
GE   77.87 (+1.12%)
F   13.55 (+3.28%)
DIS   108.29 (+2.54%)
AMC   13.79 (+12.76%)
PFE   53.58 (-0.76%)
PYPL   84.92 (+5.60%)
NFLX   194.13 (+1.43%)
LON:HGEN

HydrogenOne Capital Growth (HGEN) Share Forecast, Price & News

GBX 94.30
-0.60 (-0.63%)
(As of 05/27/2022 04:35 PM ET)
Add
Compare
Today's Range
94.20
▼
95
50-Day Range
92.30
▼
110
52-Week Range
91.50
▼
127
Volume
72,990 shs
Average Volume
281,869 shs
Market Capitalization
£121.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive HGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for HydrogenOne Capital Growth and its competitors with MarketBeat's FREE daily newsletter.

About HydrogenOne Capital Growth

Hydrogenone Capital Growth Plc focuses on investing in a portfolio of hydrogen and complementary hydrogen focused assets. The company was incorporated in 2021 and is based in London, the United Kingdom.

Headlines

May 12, 2022 | americanbankingnews.com
HydrogenOne Capital Growth plc (LON:HGEN) Insider Abigail Rotheroe Purchases 10,000 Shares of Stock
March 30, 2022 | lse.co.uk
Hydrogenone Regulatory News (HGEN)
March 29, 2022 | investing.com
Hydrogenone Capital Growth PLC (HGEN)
February 10, 2022 | nasdaq.com
Humanigen's Antibody Lenzilumab Available Through Managed Access Program For Covid-19 Patients
February 9, 2022 | nasdaq.com
Humanigen Joins Hands With Cenexi To Make Lenzilumab In France
February 9, 2022 | seekingalpha.com
Humanigen inks pact with Cenexi to make potential COVID-19 drug lenzilumab in France
February 8, 2022 | nasdaq.com
Humanigen, Inc. Common Stock (HGEN)
January 31, 2022 | nasdaq.com
Humanigen (NASDAQ:HGEN) investors are sitting on a loss of 87% if they invested a year ago
January 18, 2022 | finance.yahoo.com
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
January 5, 2022 | marketwatch.com
Humanigen Reaches Target Enrollment in Trial for Covid-19 Treatment
January 5, 2022 | seekingalpha.com
Humanigen expects data from phase 2/3 study of lenzilumab by early Q2 following enrollment
January 4, 2022 | finanznachrichten.de
Humanigen, Inc.: Humanigen to Present at Investor Conferences January 7 and 13, 2022
December 1, 2021 | ca.finance.yahoo.com
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
See More Headlines

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceutical Preparation Manufacturing
Sub-Industry
N/A
Sector
Manufacturing
Current Symbol
LON:HGEN
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.humanigen.com
Phone
16502433100
Fax
N/A
Employees
10
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
128,820,000
Free Float
N/A
Market Cap
£121.48 million
Optionable
Optionable

MarketRank™

Overall MarketRank™

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













HydrogenOne Capital Growth (LON:HGEN) Frequently Asked Questions

What is HydrogenOne Capital Growth's stock symbol?

HydrogenOne Capital Growth trades on the London Stock Exchange (LON) under the ticker symbol "HGEN."

How do I buy shares of HydrogenOne Capital Growth?

Shares of HGEN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is HydrogenOne Capital Growth's stock price today?

One share of HGEN stock can currently be purchased for approximately GBX 94.30.

How much money does HydrogenOne Capital Growth make?

HydrogenOne Capital Growth has a market capitalization of £121.48 million.

How many employees does HydrogenOne Capital Growth have?

HydrogenOne Capital Growth employs 10 workers across the globe.

What is HydrogenOne Capital Growth's official website?

The official website for HydrogenOne Capital Growth is www.humanigen.com.

How can I contact HydrogenOne Capital Growth?

HydrogenOne Capital Growth's mailing address is 533 Airport Blvd Ste 400, Burlingame, California 94010-2013. The company can be reached via phone at 16502433100.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.